2,4-diaminoquinazolines for spinal muscular atrophy

Details 2,4-diaminoquinazolines for spinal muscular atrophy 2,4-diaminoquinazolines for spinal muscular atrophy

2011-07-26

2011-07-26

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S291000, C544S359000, C546S199000, C546S268100, C548S240000, C548S335100, C548S560000, C549S059000, C549S356000, C549S398000, C549S505000

Reexamination Certificate

active

07985755

ABSTRACT:
2,4-Diaminoquinazolines of formula (I)are provided herein and are useful for treating spinal muscular atrophy (SMA).

REFERENCES:
patent: 5064833 (1991-11-01), Ife
patent: 5534518 (1996-07-01), Henrie
patent: 5616718 (1997-04-01), Henrie, II
patent: 5760230 (1998-06-01), Schohe-Loop
patent: 5874438 (1999-02-01), Schohe-Loop
patent: 5874579 (1999-02-01), Henrie, II et al.
patent: 6096499 (2000-08-01), Kozlowski et al.
patent: 6204267 (2001-03-01), Tang et al.
patent: 6248771 (2001-06-01), Shenoy et al.
patent: 6492389 (2002-12-01), Huang et al.
patent: 6635651 (2003-10-01), Uckun
patent: 6911446 (2005-06-01), Tang
patent: 2005/0065173 (2005-03-01), Jarecki
patent: WO9418980 (1994-09-01), None
patent: WO9838984 (1998-09-01), None
patent: WO9850370 (1998-11-01), None
patent: WO0059884 (2000-10-01), None
patent: WO03097615 (2003-11-01), None
patent: WO2004002961 (2004-01-01), None
patent: WO2004069255 (2004-08-01), None
patent: WO2004113305 (2004-12-01), None
patent: 2005123724 (2005-12-01), None
patent: WO 2005/123724 (2005-12-01), None
Cartegni L and Krainer AR, Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1, Nature Genetics, 2002, pp. 377-384, vol. 30, No. 4.
Brichta L et al, Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy, Human Molecular Genetics, 2003, pp. 2481-2489, vol. 12, No. 9.
Sumner CJ et al., Valproic acid increases SMN levels in spinal muscular atrophy patient cells, Annals of Neurology, 2003, pp. 647-654, vol. 54, No. 5.
Chang JG et al., Treatment of spinal muscular atrophy by sodium butyrate, PNAS, 2001, pp. 9808-9813, vol. 98, No. 17.
Andreassi C et al., Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy, Eur J Human Genetics, 2004, pp. 59-65, vol. 12.
Remenar JF et al., Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids, J Am Chem Soc, 2003, pp. 8456-8457, vol. 125.
Amrollahibiyouki MA et al., Hydroxymethylation and carbamoylation of di-and tetramethylpyridines using radical substitution (minisci) reactions, Synthetic Communications, 1998, pp. 3817-3825, vol. 28, No. 20.
Zlokarnik G et al., Quantitation of transcription and clonal selection of single living cells with B-lactamase as reporter, Science, 1998, pp. 84-88, vol. 279.
Appleman JR et al., Role of aspartate 27 in the binding of methotrexate to dihydrofolate reductase fromEscherichia coli, J Biol Chem, 1988, pp. 9187-9198, vol. 263, No. 19.
Nelson RG and Rosowsky A, Dicyclic and tricyclic diaminopyrimidine derivatives as potent inhibitors of cryptosporidium parvum dihydrofolate reductase: structure-activity and structure-selectivity correlations, Antimicrobial Agents and Chemotherapy, 2001, pp. 3293-3303, vol. 45, No. 12.
Pitman MC et al., Flashflood: A 3D field-based similarity search and alignment method for flexible molecules, J Computer-Aided Molecular Design, 2001, pp. 587-612, vol. 15.
Rosowsky A et al., 2,4-diamino-5-substituted-quinazolineass inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from pneumocystis carinii and toxoplasma gondii, J Med Chem, 1995, pp. 745-752, vol. 38.
Harris NV et al., Antifolate and antibacterial activities of 5-substituted 2,4-diaminoquinazolines, J Med Chem, 1990, pp. 434-444, vol. 33, No. 1.
Ghose AK and Crippen GM, General distance geometry three-dimensional receptor model for diverse dihydrofolate reductase inhibitors, J Med Chem, 1998, pp. 901-914, vol. 27.
Gohda K et al., Identification of Novel Potent Inhibitors for ATP-Phosphoribosyl Transferase Using Three-Dimensional Structural Database Search Technique, Quantitative Structure-Activity Relationships, 2001, pp. 143-147, vol. 20, No. 2.
Zolli-Juran M et al., High throughput screening identifies novel inhibitors ofEscherichia colidihydrofolate reductase that are competitive with dihydrofolate, Bioorganic & Medicinal Chemistry Letters, 2003, pp. 2493-2496, vol. 13, No. 15.
Jagdmann EG et al., Synthesis of 5-(4-substituted benzyl)-2, 4-diaminoquinazolines as inhibitors ofCandida albicansdihydrofolate reductase, Journal of Heterocyclic Chemistry, 1995, pp. 1461-1465, vol. 32, No. 5.
International Search Report dated Oct. 29, 2007 in connection with International Patent Application No. PCT/US2007/074971.
International Search Report dated Jun. 6, 2005 in connection with International Patent Application No. PCT/US2005/019753.
Restriction Requirement in U.S. Appl. No. 11/147,127, pp. 1-7, dated Mar. 11, 2008.
Fish and Richardson P.C., Response to Restriction Requirement in U.S. Appl. No. 11/147,127, pp. 1-4, filed Sep. 11, 2008.
Non-Final Office Action in U.S. Appl. No. 11/147,127, pp. 1-9, dated Nov. 25, 2008.
Fish and Richardson P.C., Amendment and Reply under 37 C.F.R. § 1.111 in U.S. Appl. No. 11/147,127, pp. 1-27, filed May 26, 2009.
Final Office Action in U.S. Appl. No. 11/147,127, pp. 1-8, dated Sep. 3, 2009.
Fish and Richardson P.C., Petition under 37 C.F.R. § 1.181—Premature Final Rejection in U.S. Appl. No. 11/147,127, pp. 1-4, filed Nov. 3, 2009.
Fish and Richardson P.C., Amendment and Reply to the Final Office Action Dated Sep. 3, 2009 in U.S. Appl. No. 11/147,127, pp. 1-23, filed Jan. 4, 2010.
Technology Center Director Remy Yucel, Petition Decision in U.S. Appl. No. 11/147,127, pp. 1-3, dated Jan. 8, 2010.
Interview Summary in U.S. Appl. No. 11/147,127, 4 pages, dated Jan. 14, 2010.

Affiliated with

Also associated with

Rating

2,4-diaminoquinazolines for spinal muscular atrophy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 2,4-diaminoquinazolines for spinal muscular atrophy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2,4-diaminoquinazolines for spinal muscular atrophy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2726231